m+Medelevator.RU
← Поиск публикаций
EFSA journal. European Food Safety Authority · 2021

Maximum levels of cross-contamination for 24 antimicrobial active substances in non-target feed.
Part 10: Quinolones: flumequine and oxolinic acid.

СтатьяНазвание и аннотация: Перевод пока не подготовлен
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

EFSA Panel on Biological Hazards (BIOHAZ), Koutsoumanis Konstantinos, Allende Ana, Alvarez-Ordóñez Avelino, Bolton Declan, Bover-Cid Sara, Chemaly Marianne, Davies Robert, De Cesare Alessandra, Herman Lieve, Hilbert Friederike, Lindqvist Roland, Nauta Maarten, Ru Giuseppe, Simmons Marion, Skandamis Panagiotis, Suffredini Elisabetta, Andersson Dan I, Bampidis Vasileios, Bengtsson-Palme Johan, Bouchard Damien, Ferran Aude, Kouba Maryline, López Puente Secundino, López-Alonso Marta, Nielsen Søren Saxmose, Pechová Alena, Petkova Mariana, Girault Sebastien, Broglia Alessandro, Guerra Beatriz, Innocenti Matteo Lorenzo, Liébana Ernesto, López-Gálvez Gloria, Manini Paola, Stella Pietro, Peixe Luisa

Аннотация

The specific concentrations of flumequine and oxolinic acid in non-target feed for food-producing animals, below which there would not be an effect on the emergence of, and/or selection for, resistance in bacteria relevant for human and animal health, as well as the specific antimicrobial concentrations in feed which have an effect in terms of growth promotion/increased yield were assessed by EFSA in collaboration with EMA. Details of the methodology used for this assessment, associated data gaps and uncertainties, are presented in a separate document. To address antimicrobial resistance, the Feed Antimicrobial Resistance Selection Concentration (FARSC) model developed specifically for the assessment was applied. However, due to the lack of data on the parameters required to calculate the FARSC, it was not possible to conclude the assessment until further experimental data are available. To address growth promotion, data from scientific publications obtained from an extensive literature review were used. No suitable data for the assessment were available. It was recommended to carry out studies to generate the data that are required to fill the gaps which prevented the calculation of the FARSC for these antimicrobials.

ИП Урсолов Владлен Сергеевич

ИНН 500118482352 · ОГРНИП 314500117700049

Реквизиты и контакты